ArticleJournal of pharmaceutical health care and sciences2023
Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis.
Article in Journal of pharmaceutical health care and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus-A Systematic Review and Meta-Analysis.Arthritis care & research · 2026Pooled it
- Pharmacogenetics and pharmacokinetics of immunosuppressants: clinical correlations and disease activity control in Egyptian female patients with lupus nephritis.Molecular biology reports · 2026Article
- Creatinine- and cystatin C-based population pharmacokinetic models for predicting mycophenolic acid clearance in patients with autoimmune diseases.European journal of clinical pharmacology · 2026Article
- Simultaneous Quantification of Mycophenolic Acid and Its Glucuronide Metabolite in PBMCs from Kidney Transplant Recipients by LC-MS/MS.Drug design, development and therapy · 2026Article
- Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study.Lupus science & medicine · 2025Article
- Predicting the exposure of mycophenolic acid in children with autoimmune diseases using a limited sampling strategy: A retrospective study.Clinical and translational science · 2025Article
- Published population pharmacokinetic models of mycophenolate sodium: a systematic review and external evaluation in a Chinese sample of renal transplant recipients.Frontiers in pharmacology · 2025Article
- Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant.Clinical and translational science · 2024Article
- Managing Lupus Nephritis in Children and Adolescents.Paediatric drugs · 2024Review
- Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps.Journal of clinical medicine · 2024Review
- Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.European journal of clinical pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMycophenolate mofetil (MMF), a prodrug of the immunosuppressive agent mycophenolic acid (MPA), is difficult to administer because of the pharmacokinetic complexity of MPA. Although dosage adjustment according to the 12-h area under the concentration-time curve (AUC
methodsThirty-four adult Japanese patients receiving MMF for lupus nephritis were examined retrospectively. MPA pharmacokinetics were investigated, and a PPK model was developed using Phoenix® NLME™ software. Single and double blood sampling strategies from Bayesian estimation using the PPK model and from multiple linear regression were compared. Tolerability was also evaluated.
resultsIn the pharmacokinetic analysis, renal function and serum albumin had significant effects on dose-normalized AUC
conclusionsThe present study developed the first PPK model of MPA for Japanese lupus nephritis patients. As for LSSs, a double sampling strategy at 1 and 4 h by multiple linear regression would work best; when only a single blood sampling is allowed, a strategy at 6 h by Bayesian estimation using the PPK model developed in this study would be best. The LSSs good enough for clinical use may facilitate safer, more effective, and individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.